Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer [Research Briefs]

This article is highlighted in the In This Issue feature, p. 339

Source: Cancer Discovery - April 2, 2017 Category: Cancer & Oncology Authors: Brown, K. K., Spinelli, J. B., Asara, J. M., Toker, A. Tags: Research Briefs Source Type: research